骨碎补总黄酮(强骨胶囊)治疗绝经后骨质疏松症大鼠实验的系统评价

Total flavonoids of Rhizoma Drynariae in the treatment of postmenopausal osteoporosis rats: A systematic review

目的评价骨碎补总黄酮(强骨胶囊)治疗绝经后骨质疏松症大鼠实验的有效性及安全性,探索骨碎补总黄酮(强骨胶囊)在绝经后骨质疏松症治疗领域的创新应用与安全使用。方法计算机检索国内外7个常用数据库,筛选骨碎补总黄酮(强骨胶囊)治疗绝经后骨质疏松症大鼠的随机对照试验;采用SYRCLE动物实验偏倚风险评估工具评价纳入文献研究,RevMan5.3软件进行Meta分析。结果经过初筛和严格评价,纳入12个研究,共246例样本,纳入文献质量普遍偏低。Meta分析结果显示,骨碎补总黄酮(强骨胶囊)有助于提高大鼠腰椎(WMD=0.03,95%CI 0.02~0.04,P<0.001)、股骨(WMD=0.03,95%CI 0.02~0.03,P<0.001)骨密度,以及血清骨钙素(osteocalcin,BGP)、碱性磷酸酶(alkaline phosphatase,ALP)、CTX水平,但对大鼠血清钙、血清磷水平的作用及量效关系,仍需更多动物实验加以探索与验证。安全性方面纳入文献中均未报告。结论骨碎补总黄酮(强骨胶囊)可在一定程度上提高绝经后骨质疏松症大鼠骨密度水平及部分骨代谢血液指标。但考虑到纳入研究在方法学质量和报告质量的局限性,本研究所得结论仍需进一步深入研究予以证实和深化。

Objective To evaluate the efficacy and safety of Rhizoma Drynariae total flavonoids(Qiangu Capsule)in the treatment of postmenopausal osteoporosis rats,and to explore the innovative and safe applications of Rhizoma Drynariae total flavonoids(Qiangu Capsule)in the treatment of postmenopausal osteoporosis.Methods Seven commonly used databases were went through to screen for randomized controlled trials of total flavonoids(Qiangu Capsule)for the treatment of postmenopausal osteoporotic rats.The SYRCLE animal test bias risk assessment tool was used to evaluate the quality of included studies.Results After preliminary screening and rigorous evaluation,12 studies were included,including a total of 246 samples,and the quality of the included literature was generally low.The results of meta-analysis showed that in rats Rhizoma Drynariae total flavonoids(Qiangu Capsule)could improve the bone mineral density at lumbar spine(WMD=0.03,95%CI 0.02-0.04,P<0.001)and femur(WMD=0.03,95%CI 0.02-0.03,P<0.001),as well as serum BGP,ALP and CTX levels,but the effect on serum calcium and serum phosphorus levels and the dose-effect relationship still need more animal experiments to explore and verify.Safety aspects were not reported in the literature.Conclusion The total flavonoids(Qiangu Capsule)could improve bone mineral density and some blood bone metabolic markers in postmenopausal osteoporosis rats to some extent.However,given the limitations of the number and quality of the included studies,the above conclusions need to be verified by more high-quality studies.